PEGASCY's priorities stem on rare tumors, with a particular focus on pediatric malignancies and women cancers.
We are currently investigating two new drugs:
- a small molecule kinase inhibitor of an oncogenic pathway involved in cancer survival and proliferation. This precision medicine-based compound has already checked successfully phase I trial and would be tested on patients displaying specific germline mutations
- a monoclonal antibody targeting the LINGO1 cell surface protein. Initially discovered in the brain and involved in myelinisation, this antigen is also overexpressed in Ewing Sarcoma and has thus great potential in those rare pediatric tumors. The antibody already checked successfully phase I trial in the field of neurology